Suppliers and packagers for PROSCAR

PROSCAR is finasteride (5 mg tablets). The supplier landscape is segmented by branded US supply, contract manufacturing for dosage forms, and generic/ANDA supply. Public documentation typically identifies multiple manufacturing sites and NDA/ANDA holders but often not every downstream “supplier” in distribution. Below is the practical supplier map used for procurement and diligence: labeled manufacturer/processor for the finished dosage form, key upstream API suppliers where disclosed, and the main branded and generic market sources that drive availability.

Who supplies PROSCAR finasteride 5 mg tablets in the US?

Answer: PROSCAR supply in the US is driven by the NDA holder’s labeled manufacturing network for the finished dosage form and by generic manufacturers once ANDAs launch. For the branded product, the most reliable “supplier” definition in pharma procurement is the listed manufacturer/processor on the US label (package insert) and the associated NDC product listings.

What the term “supplier” means for procurement

For high-stakes sourcing, “supplier” usually maps to one or more of:

• Finished dosage form manufacturer/processor (where the tablet is made and released).
• NDA holder (responsible for the branded product’s regulatory standing and supply obligations).
• API manufacturer (upstream active ingredient producer, sometimes disclosed via DMF cross-references).
• Distributor (often an entity like McKesson or Cardinal for branded distribution, but not the regulatory manufacturer).

What companies manufacture PROSCAR 5 mg tablets (labeled manufacturers)?

Answer: The authoritative list is the manufacturer/labeler(s) on the current PROSCAR US prescribing information and product label. This data is jurisdiction-specific and changes with site transfers.

How to diligence labeled manufacturers quickly

Procurement teams typically reconcile:

1. NDC labeler and the listed manufacturing site(s) on the package insert.
2. FDA Orange Book listings (for branded and generic finasteride 5 mg) to confirm current NDA/ANDA holders and listed patents.
3. cGMP compliance status of the labeled sites (FDA inspection history, if needed).

What patents and exclusivity control PROSCAR sourcing?

Answer: PROSCAR’s finasteride tablet supply is no longer protected by active newness exclusivity in the way it was at launch. Current supply is dominated by generic entry and any remaining formulation/process or Orange Book-listed patents (if any are still active), plus regulatory exclusivity from specific ANDA filings.

What patent estate impacts supply timing for finasteride 5 mg

• Any Orange Book-listed patents for finasteride 5 mg (NDA) can influence:
  • launch timing for ANDA products
  • whether generic manufacturers face blocking litigation via Paragraph IV challenges
• Even when the active ingredient is old, some estates can still exist around:
  • tablet formulation
  • manufacturing process
  • method-of-use (less common for finasteride in this strength because it is already established)

Which generic manufacturers supply finasteride 5 mg (PROSCAR equivalents)?

Answer: The supply baseline for finasteride 5 mg is typically a mix of:

• Large generic manufacturers with multiple ANDAs for finasteride tablets.
• Mid-size and specialty generic houses with fewer SKUs but active distribution.

How to map “who supplies” in practice

For an operational supplier map, procurement teams use:

• Orange Book to identify ANDA holders for finasteride 5 mg tablets
• NDC Directories to match each ANDA to the labeler/distributor in the market
• Contract manufacturing rosters disclosed in regulatory submissions where available

What API suppliers make finasteride for the tablet market?

Answer: The upstream finasteride API is supplied by established chemical manufacturers used by multiple tablet makers. API sourcing is commonly managed through DMF-listed manufacturers and cross-referenced filings.

How API “suppliers” are determined in diligence

• Identify the API DMF holder(s) referenced by specific ANDAs (common for generic finasteride tablets).
• Verify whether the API is made at the same site or multiple sites (often true for complex synthesis with controls and scale-out).

What contract manufacturers produce finasteride tablets for branded and generic firms?

Answer: Many finished-dose firms outsource tablet manufacturing to contract manufacturers (CMOs). The “supplier” in the CMOs sense is determined by:

• labeled manufacturing sites on product labels
• site ownership changes that occur without changing the NDA/ANDA holder

Typical manufacturing steps that drive CMO selection

• API blending and tablet compression
• uniformity and content-control testing
• coating (if applicable to the specific tablet appearance)
• packaging and stability programs

What does FDA Orange Book say about PROSCAR and finasteride 5 mg supply?

Answer: The Orange Book provides the regulated “supply gate” for ANDA launches: patent and exclusivity listings tied to the reference listed drug (RLD) and relevant strengths/dosage forms.

Practical outcome for sourcing

If an ANDA filer is blocked by an active listed patent, the impact is:

• reduced number of competing NDCs
• higher price and constrained availability in certain channels If patents are out, procurement sees:
• broader NDC availability
• stronger competition across multiple generic manufacturers

What generic entry risks exist for finasteride 5 mg equivalents?

Answer: The main risks affecting availability and supplier switching are legal and regulatory, not formulation science, for this mature product.

Key risk drivers

• Pending or recent Paragraph IV litigation for specific ANDAs
• Patent listings tied to:
  • tablet formulation improvements
  • manufacturing method claims
• Regulatory interruptions:
  • manufacturing recall events
  • facility shutdowns or consent decrees

Competitive landscape: How do branded PROSCAR and generics compare on supply?

Answer: Branded PROSCAR typically has:

• fewer manufacturing sites
• higher pricing
• tighter distributor lane control

Generic finasteride 5 mg typically has:

• more NDCs and labelers
• lower price
• multiple manufacturing options that support substitution

Commercial exposure: How much of the supply is exposed to supplier changes?

Answer: High, because finasteride is a mature small molecule with many competing tablet suppliers. The main disruption vectors are:

• CMO capacity constraints
• site-specific compliance issues
• targeted litigation against individual ANDAs that temporarily limit some NDCs

Key supplier diligence checklist for PROSCAR procurement

Answer: For any sourcing decision, the fastest and most defensible path is:

• Use the current PROSCAR label and NDC listings to identify labeled manufacturing site(s).
• Cross-check finasteride 5 mg entries in FDA Orange Book for NDA/ANDA holders with active patents.
• Map each supplier to:
  • label manufacturer/processor site
  • ANDA/NDA holder
  • API DMF reference (when available)
• Confirm supply continuity through market lead times and batch availability.

Key Takeaways

• PROSCAR “suppliers” are best defined by the labeled manufacturer/processor and the NDA holder for the finished finasteride 5 mg tablets.
• The broader finasteride 5 mg market supply is dominated by generic ANDA manufacturers, which multiply sourcing flexibility through multiple labeled NDCs.
• Upstream API suppliers are typically identified via DMF-linked references in ANDA dossiers and can differ by tablet manufacturer.
• Patent and litigation status in the Orange Book affects which generic suppliers can launch specific NDCs, influencing availability and pricing.

FAQs

1. Which NDC labeler is the “manufacturer” for PROSCAR finasteride 5 mg on US labels?
   Use the current PROSCAR prescribing information and package label to match the NDC labeler to the listed manufacturer/processor.

2. Are there any remaining Orange Book patents that delay generic finasteride 5 mg launches?
   Check FDA Orange Book for active listed patents tied to the RLD strength/dosage form; blocking litigation applies per ANDA and patent.

3. Do generic finasteride 5 mg tablets use the same API supplier as PROSCAR?
   Not necessarily; generic firms may use different DMF-referenced API manufacturers referenced in their ANDAs.

4. What typically causes finasteride tablet supply shortages in the US?
   Site-specific cGMP events, CMO capacity constraints, batch failures, and regulatory interruptions tend to be the main drivers in mature tablet categories.

5. How can a buyer validate a finasteride tablet supplier’s regulatory standing?
   Reconcile the supplier to the NDA/ANDA holder and the Orange Book listing, then confirm the labeled manufacturing site on the product label.

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Drug Label Information (NDC Directory / labeling records). U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-label-information